Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.

@article{Patick1998GenotypicAP,
  title={Genotypic and phenotypic characterization of human immunodeficiency virus type 1 variants isolated from patients treated with the protease inhibitor nelfinavir.},
  author={Amy K. Patick and M{\"u}zeyyen Duran and Yanying Cao and David L. Shugarts and Michael Keller and Elva Mazabel and Margaret Knowles and Susan Chapman and Daniel R. Kuritzkes and Martin Markowitz},
  journal={Antimicrobial agents and chemotherapy},
  year={1998},
  volume={42 10},
  pages={2637-44}
}
Nelfinavir mesylate (formerly AG1343) is a potent and selective inhibitor of human immunodeficiency virus (HIV) protease approved for the treatment of individuals infected with HIV. Nucleotide sequence analysis of protease genes from plasma HIV type 1 (HIV-1) RNA revealed a unique aspartic acid (D)-to-asparagine (N) substitution at residue 30 (D30N) in 25 of 55 patients treated with nelfinavir for a median of 13 weeks. Although the appearance of D30N was occasionally associated with concurrent… CONTINUE READING
47 Extracted Citations
53 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 47 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 53 references

Similar Papers

Loading similar papers…